LARVOL

How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with @Larvol. #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch #Cancer #CancerData #OncologyData | @brunolarvol

Neladalkib NDA Accepted for Filing with Priority Review investors.nuvalent.com/2026-05-27-Nuv… Learn more 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #FDA #FDAApproval #LungCancer #NSCLC #LCSM #Neladalkib | @alexdrilon | @JessicaJLinMD | @BenjaminBesseMD | @Alfdoc2 | @bensolomon1

Which #BreastCancer abstract are you watching at @ASCO 2026? With ASCO 2026 approaching, oncologists are sharing, discussing, and debating the most anticipated abstracts ahead of the meeting. We’re tracking these conversations in real time, analyzing what’s gaining traction across the global oncology community. Here are the top pre-conference breast cancer abstracts for ASCO 2026. Special thanks to Dr. Mike Thompson, (@mtmdphd) for the original idea. Comment “ASCO Breast” below to get the full document, including links. Explore more insights and conference data from #ACSO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #BCSM | @SuyogCancer | @A_Fushimi_MD | @to_be_elizabeth | @Lucarecco | @MamMa_mimumemo | @PTarantinoMD | @dr_yakupergun

Which #GUCancer abstract are you watching at @ASCO 2026? With ASCO 2026 approaching, oncologists are sharing, discussing, and debating the most anticipated abstracts ahead of the meeting. We’re tracking these conversations in real time, analyzing what’s gaining traction across the global oncology community. Here are the top pre-conference GU cancer abstracts for ASCO 2026. Comment “ASCO GU Trials” below to get the full document, including links. Special thanks to Dr. Mike Thompson, (@mtmdphd) for the original idea. Explore more insights and conference data from #ACSO26 👉clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GenitourinaryCancer #GUCSM | @AmandaNizamMD | @yekeduz_emre | @DrKarineTawagi | @katy_beckermann | @nataliagandur

Which #GICancer abstract are you watching at @ASCO 2026? With ASCO 2026 approaching, oncologists are sharing, discussing, and debating the most anticipated abstracts ahead of the meeting. We’re tracking these conversations in real time, analyzing what’s gaining traction across the global oncology community. Here are the top pre-conference GI cancer abstracts for ASCO 2026. Comment “ASCO GI Trials” below to get the full document, including links. Special thanks to Dr. Mike Thompson (@mtmdphd), for the original idea. Explore more insights and conference data from #ACSO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GastrointestinalCancer #GICSM | @drallysonocean | @DaisukeKotani | @Erman_Akkus | @realbowtiedoc | @GIMedOnc | @DraMartinezLago | @ronanhsieh | @rutikamehtaMD | @GillSharlene

Which #LungCancer abstract are you watching at @ASCO 2026? With ASCO 2026 approaching, oncologists are sharing, discussing, and debating the most anticipated abstracts ahead of the meeting. We’re tracking these conversations in real time, analyzing what’s gaining traction across the global oncology community. Here are the top pre-conference lung cancer abstracts for ASCO 2026. Comment “ASCO Lung” below to get the full document, including links. Special thanks to Dr. Mike Thompson, (@mtmdphd) for the original idea. Explore more insights and conference data from #ACSO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LCSM | @ADesaiMD | @AnaVManana | @christine_lovly | @chulkimMD | @Latinamd | @GlopesMd | @M_Torasawa | @DrRiyazShah | @DrSanjayPopat | @LeXiuning

Meet the @Larvol team at @ASCO 2026 | Chicago, IL 🇺🇸, May 29 - June 2 @brunolarvol, @Jud_Prz Explore more insights and conference data from #ACSO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology

Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates astrazeneca.com/media-centre/p… Learn more 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #BreastCancer #TNBC #mTNBC #BCSM #FDA #FDAApproval | @RebeccaDSing | @FernandoOnco | @ErikaHamilton9 | @hoperugo | @OncBrothers | @PTarantinoMD | @Dr_Oncologista

U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer businesswire.com/news/home/2026… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #LungCancer #NSCLC #FDA #FDAApproval #FoundationOneCDx #CompanionDiagnostic

Celebrating Phuong Ly-Gallagher (@CancerInsider) for her dedication to improving support, awareness, and outcomes within the cancer community. #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #TimesSquare | @brunolarvol | @ejgallagher1

Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates astrazeneca.com/media-centre/p… Learn more 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #BreastCancer #TNBC #mTNBC #BCSM #FDA #FDAApproval | @RebeccaDSing | @FernandoOnco | @ErikaHamilton9 | @hoperugo | @OncBrothers | @PTarantinoMD | @Dr_Oncologista

@ASCO 2026: Abstracts are out! Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology | @tompowles1 | @CathyEngMD | @HHorinouchi | @ADesaiMD | @ErikaHamilton9 | @VincentRK

Honoring our top-performing tigers with a special Times Square billboard spotlight. Thank you for your hard work, commitment, innovation, and leadership at @Larvol. The top performers at #LARVOL: Judith Pérez Granado (@Jud_Prz) | Venkateshwaran T (@VENKATE34584054) | Haris Hassan | Sowmya Sannareddy #CancerResearch #CancerData #Oncology #MedicalOncology #OncologyInsights #TimesSquare #NYC | Bruno Larvol (@brunolarvol)

@Larvol is heading to 2026 Midwest Biopharmaceutical Statistics Workshop (MBSW) in Carmel, Indiana 🇺🇸! We look forward to connecting with the oncology community and presenting: "Integrated Framework for Rapid Oncology Clinical Trial Evidence Synthesis." If you are attending, @brunolarvol and @Jud_Prz from the @Larvol team would love to grab a coffee with you and chat about oncology, cancer data, and AI. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #MBSW26 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MBSW2026 #Biopharmaceutical #OncologyClinicalTrials

LIVE FROM #TIMESSQUARE | @LARVOL Oncology Podcast | Episode #29 | Pre #ASCO26 x.com/i/broadcasts/1…

Ahead of @ASCO 2026, we asked leading AI models to forecast outcomes for key GI Cancer trials before the data drops. We analyzed 3 major GI cancer trials, generating 23 predictions across survival and response endpoints, along with 5 AI-modeled Kaplan–Meier curves to visualize how outcomes may separate over time. Each forecast includes hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, ORR, and duration of response projections across settings. Highlights: Strong multimodal signal in HCC EMERALD-3 (Liver cancer) Durvalumab + tremelimumab + lenvatinib + TACE demonstrates one of the clearest consensus efficacy signals across GI trials ▶️ AI consensus PFS HR: 0.62 ▶️ Median PFS: ~15.2 vs 8.7 months ▶️ OS improvement trends positive, though significance remains mixed across models Targeted therapy momentum in colorectal cancer NCT06008119 (BRAF-mutant colorectal cancer) Tunlametinib + vemurafenib shows consistent benefit projections versus chemotherapy-based regimens ▶️ AI consensus PFS HR: 0.59 ▶️ AI consensus OS HR: 0.72 ▶️ ORR: ~38% ▶️ DOR: ~8.5 months Adjuvant ctDNA-guided strategy: broader uncertainty CIRCULATE (Colon cancer) AI models project substantial variability in DFS outcomes for capecitabine-based escalation strategies ▶️ Wide divergence across projected median DFS estimates ▶️ Consensus confidence remains lower than other GI readouts Across trials, the AI consensus points to continued momentum for combination immunotherapy strategies in HCC, meaningful targeted therapy activity in biomarker-selected colorectal cancer, and greater uncertainty around ctDNA-guided escalation approaches in the adjuvant setting. Which ASCO 2026 GI readouts do you think will surprise and where will AI get it directionally right? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GICancer #GastrointestinalCancer #GICSM #LiverCancer #ColonCancer #ColorectalCancer | @ArndtVogel | @pashtoonkasi | @CathyEngMD | @Erman_Akkus | @GIcancerDoc

Ahead of @ASCO 2026, we asked leading AI models to forecast outcomes for key GU Cancer trials before the data drops. We analyzed 4 major GU cancer trials, generating 42 predictions across survival and response endpoints, along with 8 AI-modeled Kaplan–Meier curves to visualize how outcomes may separate over time. Each forecast includes hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, ORR, and duration of response projections across settings. Highlights: Strong AR pathway intensification signals in prostate cancer TALAPRO-3 (mCRPC) Talazoparib + enzalutamide shows one of the strongest consensus efficacy signals across GU trials ▶️ AI consensus rPFS HR: 0.51 ▶️ Median rPFS: ~35.6 vs 19.3 months ▶️ OS improvement trends positive but remains less certain PROTEUS (Localized prostate cancer) Apalutamide + ADT demonstrates consistent benefit across metastasis-free and event-free survival endpoints ▶️ AI consensus MFS HR: 0.65 ▶️ AI consensus EFS HR: 0.65 ▶️ pCR: ~19% Renal cancer: modest directional improvement RAMPART (Renal) Adjuvant durvalumab trends toward DFS improvement, though significance remains inconsistent across models ▶️ AI consensus DFS HR: 0.84 ▶️ OS separation appears limited in current projections Ovarian cancer: clearer PFS than OS signal CHIPRO (Ovarian) Chiauranib + paclitaxel shows consistent PFS benefit projections ▶️ AI consensus PFS HR: 0.70 ▶️ Median PFS: ~6.6 vs 4.6 months ▶️ OS significance remains uncertain across models ▶️ ORR: ~35% Across trials, the AI consensus points to continued momentum for AR-targeted intensification strategies in prostate cancer, more modest expectations for adjuvant immunotherapy in renal cancer, and clearer PFS than OS differentiation in ovarian cancer. Which ASCO 2026 GU readouts do you think will surprise and where will AI get it directionally right? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GenitourinaryCancer #GUCSM #OvarianCancer #RenalCancer #KidneyCancer #ProstateCancer | @DrChoueiri | @DrYukselUrun | @montypal | @TiansterZhang | @UroDocAsh

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia globenewswire.com/news-release/2… Learn more 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #RRAML #AcuteMyeloidLeukemia #Leukemia #LEUSM

Ahead of @ASCO 2026, we asked leading AI models to forecast outcomes for key Breast Cancer trials before the data drops. We analyzed 7 major breast cancer trials, generating 43 predictions across survival and response endpoints, along with 8 AI-modeled Kaplan–Meier curves to visualize how outcomes may separate over time. Each forecast includes hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, ORR, and duration of response projections across settings. Highlights: Strong ADC momentum in TNBC BL-B01D1-307 (TNBC) Izalontamab brengitecan shows one of the strongest consensus signals across models ▶️ AI consensus PFS HR: 0.51 ▶️ AI consensus OS HR: 0.64 ▶️ ORR: ~44% ASCENT-04 (TNBC) Sacituzumab govitecan + pembrolizumab trends toward durable downstream benefit ▶️ AI consensus PFS2 HR: 0.72 ▶️ Consistent statistical significance across all models ESR1-directed strategy: directional support SERENA-6 (HR+/HER2-) Camizestrant + CDK4/6i demonstrates a clear PFS2 signal after molecular progression ▶️ AI consensus PFS2 HR: 0.64 ▶️ Median PFS2: ~23.2 vs 16.9 months HER2+ landscape: activity with mixed confidence KN026-004 (HER2+) Anbenitamab-based therapy trends toward EFS improvement, though significance remains inconsistent across models ▶️ AI consensus EFS HR: 0.71 ▶️ tpCR: ~62% Endocrine backbone optimization: limited differentiation PATHWAY (HER2-) Palbociclib + tamoxifen shows modest OS directionality ▶️ AI consensus OS HR: 0.81 ▶️ Statistical significance remains uncertain persevERA BC (HR+/HER2-) Giredestrant + palbociclib shows limited separation from standard ET ▶️ AI consensus PFS HR: 0.90 ▶️ Models consistently predict non-significant outcomes Across trials, the AI consensus points to continued ADC momentum in TNBC, meaningful potential for ESR1-guided therapeutic switching, and more modest expectations for endocrine backbone replacement strategies. Which ASCO 2026 breast cancer trial do you think will surprise and where will AI get it directionally right? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/abs… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #BreastCancer #BCSM #TNBC | @dr_yakupergun | @matteolambe | @stolaney1 | @ErikaHamilton9 | @DrSGraff